Health benefits of resveratrol: Evidence from clinical studies
Top Cited Papers
- 11 February 2019
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 39 (5) , 1851-1891
Abstract
Resveratrol is a polyphenolic nutraceutical that exhibits pleiotropic activities in human subjects. The efficacy, safety, and pharmacokinetics of resveratrol have been documented in over 244 clinical trials, with an additional 27 clinical trials currently ongoing. Resveretrol is reported to potentially improve the therapeutic outcome in patients suffering from diabetes mellitus, obesity, colorectal cancer, breast cancer, multiple myeloma, metabolic syndrome, hypertension, Alzheimer's disease, stroke, cardiovascular diseases, kidney diseases, inflammatory diseases, and rhinopharyngitis. The polyphenol is reported to be safe at doses up to 5 g/d, when used either alone or as a combination therapy. The molecular basis for the pleiotropic activities of resveratrol are based on its ability to modulate multiple cell signaling molecules such as cytokines, caspases, matrix metalloproteinases, Wnt, nuclear factor‐κB, Notch, 5′‐AMP‐activated protein kinase, intercellular adhesion molecule, vascular cell adhesion molecule, sirtuin type 1, peroxisome proliferator‐activated receptor‐γ coactivator 1α, insulin‐like growth factor 1, insulin‐like growth factor‐binding protein 3, Ras association domain family 1α, pAkt, vascular endothelial growth factor, cyclooxygenase 2, nuclear factor erythroid 2 like 2, and Kelch‐like ECH–associated protein 1. Although the clinical utility of resveratrol is well documented, the rapid metabolism and poor bioavailability have limited its therapeutic use. In this regard, the recently produced micronized resveratrol formulation called SRT501, shows promise. This review discusses the currently available clinical data on resveratrol in the prevention, management, and treatment of various diseases and disorders. Based on the current evidence, the potential utility of this molecule in the clinic is discussed.Keywords
Funding Information
- Anusandhan National Research Foundation (ECR/2016/000034, PDF/2016/004063)
- University Grants Commission (No. F.30-112/2015 (BSR))
- Department of Biotechnology, Government of West Bengal (DBT/2017/BHU/786)
- Indian Council of Medical Research (3/2/2/43/2018/Online Onco Fship/NCD-III)
This publication has 242 references indexed in Scilit:
- Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic StrokeFrontiers in Neurology, 2013
- Grape Resveratrol Increases Serum Adiponectin and Downregulates Inflammatory Genes in Peripheral Blood Mononuclear Cells: A Triple-Blind, Placebo-Controlled, One-Year Clinical Trial in Patients with Stable Coronary Artery DiseaseCardiovascular Drugs and Therapy, 2012
- Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysisThe Lancet, 2012
- IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030Diabetes Research and Clinical Practice, 2011
- Interdependence of AMPK and SIRT1 for Metabolic Adaptation to Fasting and Exercise in Skeletal MuscleCell Metabolism, 2010
- Oxidized Low-Density Lipoprotein2009
- Models for prevention and treatment of cancer: Problems vs promisesBiochemical Pharmacology, 2009
- Chronic Kidney Disease and Its ComplicationsPrimary Care: Clinics in Office Practice, 2008
- Resveratrol: A review of preclinical studies for human cancer preventionToxicology and Applied Pharmacology, 2007
- Tracking the dephosphorylation of resveratrol triphosphate in skin by confocal Raman microscopyJournal of Controlled Release, 2007